TDMS Study 05187-06 Pathology Tables
NTP Experiment-Test: 05187-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYLEUGENOL Date: 07/20/98
Route: GAVAGE Time: 10:21:48
CORE STUDY
Facility: Battelle Columbus Laboratory
Chemical CAS #: 93-15-2
Lock Date: 06/12/96
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05187-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYLEUGENOL Date: 07/20/98
Route: GAVAGE Time: 10:21:48
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 37 MG/KG 75 MG/KG 150
MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Moribund Sacrifice 5 7 8 13
Natural Death 14 24 23 35
Dosing Accident 1 1
Survivors
Natural Death 2
Terminal Sacrifice 31 18 16 2
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (38) (28) (30) (24)
Intestine Large, Colon (50) (50) (48) (47)
Intestine Large, Rectum (50) (50) (49) (48)
Leiomyosarcoma 1 (2%)
Intestine Small, Duodenum (46) (49) (46) (43)
Intestine Small, Jejunum (46) (46) (40) (40)
Carcinoma 1 (3%)
Liver (50) (50) (49) (50)
Carcinoma, Metastatic, Ureter 1 (2%)
Fibrosarcoma, Metastatic, Mesentery 1 (2%)
Fibrosarcoma, Metastatic, Skin 1 (2%) 1 (2%)
Hemangioma 1 (2%)
Hemangiosarcoma, Metastatic, Spleen 1 (2%)
Hepatoblastoma 6 (12%) 11 (22%) 11 (22%)
Hepatoblastoma, Multiple 4 (8%)
Hepatocellular Carcinoma 7 (14%) 13 (26%) 18 (37%) 9 (18%)
Hepatocellular Carcinoma, Multiple 24 (48%) 29 (59%) 38 (76%)
Hepatocellular Adenoma 12 (24%) 9 (18%) 8 (16%) 9 (18%)
Hepatocellular Adenoma, Multiple 8 (16%) 39 (78%) 38 (78%) 32 (64%)
Hepatocholangiocarcinoma 2 (4%)
Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%)
Mast Cell Tumor Malignant 1 (2%)
Osteosarcoma, Metastatic, Uncertain Primary
Site 1 (2%)
Plasma Cell Tumor Malignant 1 (2%)
Schwannoma Malignant, Metastatic, Mesentery 1 (2%)
Mesentery (13) (7) (3) (3)
Fibrosarcoma 1 (8%)
Fibrosarcoma, Metastatic, Skin 1 (14%) 1 (33%)
Schwannoma Malignant 1 (14%) 1 (33%)
Pancreas (49) (50) (46) (46)
NTP Experiment-Test: 05187-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYLEUGENOL Date: 07/20/98
Route: GAVAGE Time: 10:21:48
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 37 MG/KG 75 MG/KG 150
MG/KG
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Fibrosarcoma, Metastatic, Mesentery 1 (2%)
Fibrosarcoma, Metastatic, Skin 1 (2%) 1 (2%)
Schwannoma Malignant, Metastatic, Mesentery 1 (2%) 1 (2%)
Salivary Glands (50) (45) (44) (42)
Stomach, Forestomach (50) (50) (48) (46)
Squamous Cell Carcinoma 1 (2%)
Squamous Cell Papilloma 1 (2%) 1 (2%)
Stomach, Glandular (45) (49) (46) (45)
Tooth (2) (1)
Odontoma 1 (50%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (48) (44)
Histiocytic Sarcoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (50) (50) (49)
Adenoma 1 (2%)
Fibrosarcoma, Metastatic, Mesentery 1 (2%)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%)
Plasma Cell Tumor Malignant 1 (2%)
Adrenal Medulla (50) (50) (50) (49)
Pheochromocytoma Benign 2 (4%) 1 (2%)
Bilateral, Pheochromocytoma Benign 1 (2%)
Islets, Pancreatic (49) (50) (46) (47)
Adenoma 1 (2%)
Pituitary Gland (48) (44) (44) (40)
Pars Distalis, Adenoma 5 (10%) 1 (2%) 1 (3%)
Thyroid Gland (50) (46) (46) (42)
Follicular Cell, Adenoma 2 (4%) 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Peritoneum (1)
Schwannoma Malignant, Metastatic, Mesentery 1 (100%)
____________________________________________________________________________________________________________________________________
NTP Experiment-Test: 05187-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYLEUGENOL Date: 07/20/98
Route: GAVAGE Time: 10:21:48
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 37 MG/KG 75 MG/KG 150
MG/KG
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (50) (49) (48) (41)
Cystadenoma 3 (6%)
Fibrosarcoma, Metastatic, Mesentery 1 (2%)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Luteoma 1 (2%) 1 (2%)
Schwannoma Malignant, Metastatic, Mesentery 1 (2%)
Uterus (50) (50) (49) (47)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Polyp Stromal 1 (2%)
Vagina (1)
Leiomyosarcoma, Metastatic, Intestine Large,
Rectum 1 (100%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (48) (50)
Hemangiosarcoma 1 (2%)
Mast Cell Tumor Malignant 1 (2%)
Plasma Cell Tumor Malignant 1 (2%)
Lymph Node (13) (7) (8) (4)
Mediastinal, Fibrosarcoma, Metastatic, Skin 1 (13%)
Mediastinal, Hepatocellular Carcinoma,
Metastatic, Liver 1 (25%)
Mediastinal, Histiocytic Sarcoma 1 (25%)
Lymph Node, Mandibular (49) (43) (41) (32)
Histiocytic Sarcoma 1 (3%)
Lymph Node, Mesenteric (47) (48) (43) (36)
Fibrosarcoma, Metastatic, Mesentery 1 (2%)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Schwannoma Malignant, Metastatic, Mesentery 1 (2%)
Spleen (50) (50) (46) (46)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Mast Cell Tumor Malignant 1 (2%)
Plasma Cell Tumor Malignant 1 (2%)
Thymus (45) (43) (40) (33)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (50) (48) (50) (37)
Adenoma 1 (2%)
Carcinoma 1 (2%)
Skin (50) (50) (50) (49)
NTP Experiment-Test: 05187-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYLEUGENOL Date: 07/20/98
Route: GAVAGE Time: 10:21:48
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 37 MG/KG 75 MG/KG 150
MG/KG
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM - cont
Subcutaneous Tissue, Fibrosarcoma 4 (8%) 1 (2%)
Subcutaneous Tissue, Schwannoma Malignant 1 (2%)
Subcutaneous Tissue, Pinna, Fibrosarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (2) (8) (3) (3)
Fibrosarcoma, Metastatic, Skin 1 (13%)
Hemangiosarcoma 1 (33%)
Schwannoma Malignant, Metastatic, Skin 1 (50%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (47) (46) (41)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (48) (45)
Alveolar/Bronchiolar Adenoma 5 (10%) 4 (8%) 1 (2%) 1 (2%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%)
Alveolar/Bronchiolar Carcinoma 1 (2%) 1 (2%)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Carcinoma, Metastatic, Ureter 1 (2%)
Hepatoblastoma, Metastatic, Liver 3 (6%) 4 (9%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%) 7 (14%) 23 (48%) 26 (58%)
Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%)
Osteosarcoma, Metastatic, Uncertain Primary
Site 1 (2%)
Mediastinum, Fibrosarcoma, Metastatic,
Mesentery 1 (2%)
Nose (50) (50) (49) (47)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (2) (1)
Carcinoma, Metastatic, Harderian Gland 1 (50%)
Harderian Gland (5) (2) (2)
Adenoma 2 (100%) 2 (100%)
Carcinoma 5 (100%)
____________________________________________________________________________________________________________________________________
NTP Experiment-Test: 05187-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYLEUGENOL Date: 07/20/98
Route: GAVAGE Time: 10:21:48
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 37 MG/KG 75 MG/KG 150
MG/KG
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (50) (49)
Hemangioma 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%)
Ureter (1)
Transitional Epithelium, Carcinoma 1 (100%)
Urinary Bladder (50) (49) (47) (46)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%)
Lymphoma Malignant 15 (30%) 8 (16%) 8 (16%) 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 6
NTP Experiment-Test: 05187-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYLEUGENOL Date: 07/20/98
Route: GAVAGE Time: 10:21:48
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 37 MG/KG 75 MG/KG 150
MG/KG
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 41 50 49 49
Total Primary Neoplasms 79 116 128 116
Total Animals with Benign Neoplasms 29 49 46 42
Total Benign Neoplasms 39 57 57 47
Total Animals with Malignant Neoplasms 27 42 48 49
Total Malignant Neoplasms 40 59 71 69
Total Animals with Metastatic Neoplasms 5 10 26 30
Total Metastatic Neoplasm 11 19 36 34
Total Animals with Malignant Neoplasms 1
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
NTP Experiment-Test: 05187-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYLEUGENOL Date: 07/20/98
Route: GAVAGE Time: 10:21:48
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 37 MG/KG 75 MG/KG 150
MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Moribund Sacrifice 5 6 5 9
Natural Death 6 8 7 4
Accidently Killed 1 1
Dosing Accident 1
Survivors
Terminal Sacrifice 38 36 37 35
Missing 1
Animals Examined Microscopically 49 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Cecum (49) (50) (48) (50)
Carcinoma 1 (2%) 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Intestine Small, Duodenum (47) (47) (48) (50)
Polyp Adenomatous 1 (2%)
Intestine Small, Jejunum (49) (49) (48) (48)
Carcinoma 1 (2%)
Intestine Small, Ileum (48) (48) (49) (50)
Liver (49) (50) (50) (50)
Hemangiosarcoma 2 (4%) 1 (2%)
Hemangiosarcoma, Multiple 1 (2%) 1 (2%)
Hemangiosarcoma, Metastatic, Bone Marrow 1 (2%)
Hemangiosarcoma, Metastatic, Skeletal Muscle 1 (2%)
Hepatoblastoma 1 (2%) 2 (4%)
Hepatoblastoma, Multiple 1 (2%)
Hepatocellular Carcinoma 9 (18%) 17 (34%) 16 (32%) 7 (14%)
Hepatocellular Carcinoma, Multiple 1 (2%) 3 (6%) 3 (6%) 2 (4%)
Hepatocellular Adenoma 13 (27%) 10 (20%) 5 (10%) 10 (20%)
Hepatocellular Adenoma, Multiple 13 (27%) 33 (66%) 33 (66%) 29 (58%)
Mast Cell Tumor Malignant 1 (2%)
Mesentery (1) (2) (1) (1)
Fibrous Histiocytoma 1 (50%)
Hemangiosarcoma, Metastatic, Lymph Node,
Mesenteric 1 (100%)
Oral Mucosa (1)
Pharyngeal, Squamous Cell Carcinoma 1 (100%)
Pancreas (49) (49) (50) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Fibrous Histiocytoma, Metastatic, Lymph Node 1 (2%)
NTP Experiment-Test: 05187-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYLEUGENOL Date: 07/20/98
Route: GAVAGE Time: 10:21:48
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 37 MG/KG 75 MG/KG 150
MG/KG
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Fibrous Histiocytoma, Metastatic, Mesentery 1 (2%)
Mast Cell Tumor Malignant 1 (2%)
Salivary Glands (49) (50) (50) (50)
Stomach, Forestomach (49) (50) (50) (50)
Squamous Cell Papilloma 1 (2%) 2 (4%)
Stomach, Glandular (49) (48) (49) (50)
Carcinoma 1 (2%)
Neuroendocrine Tumor, Malignant 2 (4%)
Tooth (23) (13) (4) (5)
Odontoma 1 (4%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (49) (50) (50) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%) 1 (2%)
Fibrous Histiocytoma, Metastatic, Mesentery 1 (2%)
Hemangiosarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (49) (50) (50) (50)
Adenoma 1 (2%) 1 (2%)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Islets, Pancreatic (49) (49) (50) (50)
Adenoma 1 (2%)
Thyroid Gland (49) (50) (50) (50)
Follicular Cell, Adenoma 1 (2%) 1 (2%) 1 (2%)
Follicular Cell, Carcinoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (49) (50) (50) (50)
Fibrous Histiocytoma, Metastatic, Mesentery 1 (2%)
Preputial Gland (49) (50) (50) (50)
Prostate (49) (50) (50) (50)
Carcinoma 1 (2%)
Seminal Vesicle (49) (50) (50) (50)
NTP Experiment-Test: 05187-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYLEUGENOL Date: 07/20/98
Route: GAVAGE Time: 10:21:48
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 37 MG/KG 75 MG/KG 150
MG/KG
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - cont
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Fibrous Histiocytoma, Metastatic, Mesentery 1 (2%)
Testes (49) (50) (50) (50)
Interstitial Cell, Adenoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (49) (49) (50) (50)
Hemangioma 1 (2%)
Hemangiosarcoma 1 (2%) 1 (2%)
Hemangiosarcoma, Metastatic, Spleen 1 (2%) 1 (2%)
Hemangiosarcoma, Metastatic, Skeletal Muscle 1 (2%)
Lymph Node (3) (4) (5) (3)
Lumbar, Fibrous Histiocytoma, Metastatic,
Mesentery 1 (25%)
Mediastinal, Fibrous Histiocytoma,
Metastatic, Mesentery 1 (25%)
Pancreatic, Fibrous Histiocytoma 1 (20%)
Renal, Fibrous Histiocytoma, Metastatic,
Mesentery 1 (25%)
Lymph Node, Mandibular (48) (46) (47) (45)
Lymph Node, Mesenteric (49) (46) (49) (50)
Fibrous Histiocytoma, Metastatic, Mesentery 1 (2%)
Hemangiosarcoma 1 (2%)
Hemangiosarcoma, Metastatic, Spleen 1 (2%)
Spleen (49) (49) (50) (50)
Hemangioma 1 (2%)
Hemangiosarcoma 2 (4%) 2 (4%)
Hemangiosarcoma, Metastatic, Skeletal Muscle 1 (2%)
Mast Cell Tumor Malignant 1 (2%)
Thymus (37) (40) (38) (45)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (3%)
Fibrous Histiocytoma, Metastatic, Mesentery 1 (3%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (49) (50) (50) (50)
Subcutaneous Tissue, Fibrosarcoma 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
NTP Experiment-Test: 05187-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYLEUGENOL Date: 07/20/98
Route: GAVAGE Time: 10:21:48
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 37 MG/KG 75 MG/KG 150
MG/KG
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (49) (50) (50) (50)
Vertebra, Osteosarcoma 1 (2%)
Skeletal Muscle (2) (1) (3) (3)
Hemangiosarcoma 1 (50%) 1 (33%) 2 (67%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (49) (50) (50) (50)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (49) (50) (50) (50)
Alveolar/Bronchiolar Adenoma 10 (20%) 9 (18%) 17 (34%) 14 (28%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%) 1 (2%) 2 (4%) 1 (2%)
Alveolar/Bronchiolar Carcinoma 4 (8%) 4 (8%) 5 (10%) 6 (12%)
Alveolar/Bronchiolar Carcinoma, Multiple 1 (2%) 2 (4%)
Fibrous Histiocytoma, Metastatic, Mesentery 1 (2%)
Hemangiosarcoma, Metastatic, Skeletal Muscle 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 2 (4%) 6 (12%) 7 (14%) 4 (8%)
Osteosarcoma, Metastatic, Uncertain Primary
Site 1 (2%)
Mediastinum, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 1 (2%) 2 (4%)
Mediastinum, Fibrous Histiocytoma,
Metastatic, Mesentery 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (4) (1) (7) (6)
Adenoma 4 (100%) 1 (100%) 7 (100%) 6 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (49) (50) (50) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%) 1 (2%)
Fibrous Histiocytoma, Metastatic, Mesentery 1 (2%)
Urinary Bladder (49) (50) (50) (50)
NTP Experiment-Test: 05187-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYLEUGENOL Date: 07/20/98
Route: GAVAGE Time: 10:21:48
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 37 MG/KG 75 MG/KG 150
MG/KG
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(49) *(50) *(50) *(50)
Lymphoma Malignant 3 (6%) 3 (6%) 8 (16%) 6 (12%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 12
NTP Experiment-Test: 05187-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYLEUGENOL Date: 07/20/98
Route: GAVAGE Time: 10:21:48
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 37 MG/KG 75 MG/KG 150
MG/KG
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 41 48 49 45
Total Primary Neoplasms 69 92 111 102
Total Animals with Benign Neoplasms 33 43 42 44
Total Benign Neoplasms 44 57 68 65
Total Animals with Malignant Neoplasms 23 29 32 29
Total Malignant Neoplasms 25 35 43 35
Total Animals with Metastatic Neoplasms 6 9 10 6
Total Metastatic Neoplasm 13 20 15 6
Total Animals with Malignant Neoplasms 1
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant 2
Total Uncertain Neoplasms 2
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------